ANDA 90819, held by Actavis Elizabeth. Buprenorphine Hydrochloride.
As of Nov 16, 2026, ANDA 90819 (Buprenorphine Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Feb 19, 2015, with 23 approved supplements and 0 published complete response letters.
Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 19, 2015 | Original application | Approved |
| Buprenorphine HydrochlorideEQ 2MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Buprenorphine HydrochlorideEQ 8MG BASE · tablet;sublingual | Buprenorphine Hydrochloride | Rx |
| Aug 14, 2026 | Supplement 40REMS | Approved | None posted |
| Dec 31, 2025 | Supplement 38Labeling · Standard review | Approved | None posted |
| Feb 21, 2025 | Supplement 36REMS | Approved | None posted |
| Mar 20, 2024 | Supplement 29REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| Jun 14, 2023 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jun 14, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 28REMS | Approved | None posted |
| Jun 17, 2022 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jun 17, 2022 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jun 14, 2022 | Supplement 23Labeling · Standard review | Approved | None posted |
| May 3, 2022 | Supplement 25REMS | Approved | None posted |
| Mar 4, 2021 | Supplement 21Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 31, 2018 | Supplement 15REMS | Approved | None posted |
| Feb 1, 2018 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 31, 2018 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 23, 2017 | Supplement 8REMS | Approved | None posted |
| Dec 16, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 7, 2016 | Supplement 4REMS | Approved | None posted |
| Feb 19, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters